The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Individual variability in drug efficacy and drug safety is a major challenge in current clinical
practice, drug development, and drug regulation. For more than 5 decades, studies of …

Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole,
dexlansoprazole, pantoprazole, and rabeprazole, were shown to be weak inhibitors of …

Clopidogrel pharmacotherapy is associated with substantial interindividual variability in
clinical response, which can translate into an increased risk of adverse outcomes …

Dasabuvir is mainly metabolized by cytochrome P450 (CYP) 2C8 and is predominantly used
in a regimen containing ritonavir. Ritonavir and clopidogrel are inhibitors of CYP3A4 and …

Extracellular nucleotides, such as ATP and UTP, have distinct signaling roles through a
class of G-protein-coupled receptors, termed P2Y. The receptor ligands are typically …

Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …

Objectives: We aimed to investigate the biological impact of a tailored clopidogrel loading
dose (LD) according to platelet reactivity monitoring in carriers of the cytochrome (CYP) …

Under the guidance of the International Consortium for Innovation and Quality in
Pharmaceutical Development (IQ), scientists from 20 pharmaceutical companies formed a …

Human arylacetamide deacetylase (AADAC) is an esterase responsible for the hydrolysis of
some drugs, including flutamide, indiplon, phenacetin, and rifamycins. AADAC is highly …